A recent study has discovered that NAADP-induced Ca2+ release was blocked by genetic silencing of TPC1, and a pharmacological and genetic blockade of TPC1 dramatically reduced fetal bovine serum (FBS) and induced Ca2+ release and proliferation of metastatic colorectal cancer (mCRC) cells established from liver metastasis of human patients, thereby hinting at TPC1 being a novel therapeutic target in mCRC patients [108]. This evidence concerns the gene TPCN1 and metastatic colorectal cancer.